Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21071715.
- Also identified by DOI 10.1161/CIRCRESAHA.110.223883 and PMC identifier 3027152.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The resolution of acute inflammation is a process that allows for inflamed tissues to return to homeostasis. Resolution was held to be a passive process, a concept now overturned with new evidence demonstrating that resolution is actively orchestrated by distinct cellular events and endogenous chemical mediators. Among these, lipid mediators, such as the lipoxins, resolvins, protectins, and newly identified maresins, have emerged as a novel genus of potent and stereoselective players that counter-regulate excessive acute inflammation and stimulate molecular and cellular events that define resolution. Given that uncontrolled, chronic inflammation is associated with many cardiovascular pathologies, an appreciation of the endogenous pathways and mediators that control timely resolution can open new terrain for therapeutic approaches targeted at stimulating resolution of local inflammation, as well as correcting the impact of chronic inflammation in cardiovascular disorders. Here, we overview and update the biosynthesis and actions of proresolving lipid mediators, highlighting their diverse protective roles relevant to vascular systems and their relation to aspirin and statin therapies.
Medical subject headings
- Anti-Inflammatory Agents
- Aspirin
- Cardiovascular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Inflammation
- Inflammation Mediators
- Lipid Metabolism